Targeted-release budesonide in immunoglobulin A nephropathy; a mini-review

Immunoglobulin A nephropathy is the most common kind of primary glomerulonephritis worldwide and one main causes renal failure. Systemic corticosteroid therapy may protect against deterioration in IgA nephropathy; however, it not often advised for long-term treatment due to possible side effects. Recent studies present promising results new targeted-release formulation budesonide that delivers drug distal ileum reduce effects patients with nephropathy. In this paper, we highlighted potential benefits as a option need additional confirm its effectiveness. The lack alternative treatments prevent without other systemic motivated us gather relevant information fill gap. brief overview, have reviewed some recently published regarding how protects Studies reveal might significantly decrease proteinuria, hematuria, creatinine level while maintaining normal function. Though, limited number trials been established date, further investigations are needed benefit treating